Globeimmune, Inc. (OTCMKTS:GBIM – Get Free Report) shares crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $0.00 and traded as high as $0.0001. Globeimmune shares last traded at $0.00, with a volume of 0 shares.
Globeimmune Trading Down 100.0%
Globeimmune Company Profile
GlobeImmune, Inc was a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company’s research was based on its Tarmogen platform, which used genetically engineered yeast to present disease-associated antigens and stimulate targeted immune responses.
GlobeImmune’s historical development programs included GI-4000, an investigational therapeutic vaccine designed to target cancer-associated KRAS mutations, as well as other vaccine candidates aimed at solid tumors and chronic viral infections.
Further Reading
- Five stocks we like better than Globeimmune
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Globeimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globeimmune and related companies with MarketBeat.com's FREE daily email newsletter.
